Live Breaking News & Updates on Catalym Gmb

Stay updated with breaking news from Catalym gmb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER" ....

Mccormick-place , Illinois , United-states , Chicago , American , Phil-lhuilier , Ignacio-melero-bermejo , Catalym-gmb , Alison-opalko , Trophic-communications , Oncology-congress , American-society-of-clinical-oncology

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Spain , Geneva , Genè , Switzerland , Ignacio-melero , Phil-lhuillier , Catalym-gmb , Oncology-congress , Department-of-immunology , International-coordinating-investigator-prof , European-society-for-medical-oncology , Trophic-communications

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , Phil-lhuillier , Christine-schuberth-wagner , Catalym-gmb , Trophic-communications , Society-for-immunotherapy-of-cancer , Chief-scientific-officer , Central-mediator , T-cell-engager , Ted-human-effector-cell-relocation

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Italy , Milan , Lombardia , Catalym-gmb , Phil-lhuilier , Andrea-necchi , Phil-lhuillier , Trophic-communications , Genitourinary-medical-oncology , Raffaele-hospital , Principal-investigator , Phill-huillier

CatalYm Presents Data at ESMO 2023 Expanding GDF-15's Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

CatalYm Presents Data at ESMO 2023 Expanding GDF-15's Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Spain , Madrid , Phil-lhuilier , Catalym-gmb , Christine-schuberth-wagner , Nature-communications , Trophic-communications , European-society-for-medical-oncology , European-society , Medical-oncology , Chief-scientific-officer , Ted-human-effector-cell-relocation